Related Experiment Video

Updated: Mar 11, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

6.9K

Full antagonism of the estrogen receptor without a prototypical ligand side chain

Sathish Srinivasan1, Jerome C Nwachukwu1, Nelson E Bruno1

  • 1Department of Cancer Biology, The Scripps Research Institute, Jupiter, Florida, USA.

Nature Chemical Biology
|November 22, 2016
PubMed

Insights

Researchers developed novel estrogen receptor-alpha (ERα) antagonists to overcome endocrine therapy resistance in breast cancer. These new ligands offer a distinct chemical approach for improved treatment and reduced side effects.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Drug Discovery

Background:

  • Endocrine therapies are crucial for estrogen receptor-alpha (ERα)-positive breast cancer but face resistance.
  • On-target side effects limit patient compliance and chemoprevention efficacy, necessitating new therapeutic strategies.

Purpose of the Study:

  • To design and characterize a novel series of full-antagonist ligands for ERα.
  • To explore a new structural mechanism for ERα antagonism and degradation, distinct from traditional ligands.

Main Methods:

  • Utilized structure-based design principles to create new ERα antagonist ligands.
  • Employed crystal structures and phenotypic assays to analyze ligand-receptor interactions and functional outcomes.

Main Results:

  • Developed a series of ERα antagonists lacking the conventional side chain, demonstrating a novel antagonism mechanism.
  • Identified separate design elements for receptor antagonism and degradation, opening new avenues for ligand optimization.
  • Revealed a distinct chemical space for future ligand development.

Conclusions:

  • This work presents a new class of ERα ligands with potential to overcome endocrine resistance in breast cancer.
  • The findings provide a structure-based strategy for designing ligands with tailored ERα-mediated effects.
  • Understanding these structural rules has broad implications for estrogen-sensitive conditions beyond cancer, including bone homeostasis, metabolism, and autoimmunity.

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.3K
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.4K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.5K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K